Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 17Other hematologic neoplasm 7Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

Cytarabine 13fludarabine phosphate 10Etoposide 8Methotrexate 7Cyclophosphamide 7Busulfan 7Idarubicin 6Daunorubicin 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Cyclosporine 5Antilymphocyte Serum 5Vorinostat 4Tacrolimus 4Radiotherapy 4Mitoxantrone 4Lenalidomide 4Epoetin Alfa 4Azacitidine 4sargramostim 3merphos 3epoetin beta 3Topotecan 3Thioguanine 3Methylprednisolone 3Granulocyte-Macrophage Colony-Stimulating Factor 3Dexamethasone 3Decitabine 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × CT-P10 × Classical hematology × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡